{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:54:35Z","timestamp":1778651675197,"version":"3.51.4"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study aims to evaluate the vismodegib treatment in local advanced (laBCC) and metastatic (mBCC) basal cell carcinoma. The data of 29 patients were retrospectively reviewed. The clinical and histopathological features of the patients and adverse events of vismodegib were recorded. Overall survival (OS) and progression\u2010free survival (PFS) were evaluated with Kaplan\u2013Meier analysis. The median follow\u2010up period was 17\u2009months (range: 1.6\u201357.3), and the median age at diagnosis 73\u2009years (range: 39\u201388). The most common disease location was head and neck (86.2%), and the most common non\u2010skin sites of disease were lymph nodes (13.8%), bone (13.8%), lung (6.9%), and brain (6.9%). Three (10.3%) patients had Gorlin's syndrome. The number of metastatic patients was 5 (17.2%). With vismodegib treatment, the complete response rate was 27.6%, partial response 55.2%, and stable response 10.3%. Treatment responses were most frequently seen within 2 months from the beginning of vismodegib. The median OS was 43.3\u2009\u00b1\u20099.0\u00a0months (25.6\u201361.1) for all patients. The median PFS in the laBCC was 15.7\u2009\u00b1\u20091.8\u00a0months (12.2\u201319.3), and 12.1\u2009\u00b1\u20094.6\u00a0months (2.9\u201321.2) in the mBCC. In the univariable analysis for the OS, only the treatment after the vismodegib was statistically significant, showing chemotherapy was better comparing to no treatment or surgery. The most common adverse events were fatigue\u201058.6%, muscle spasms\u201048.3%, alopecia\u201013.8%, and weight loss\u201013.8%. This real\u2010life data study shows that vismodegib treatment in locally advanced and metastatic BCC was well tolerated and effective.<\/jats:p>","DOI":"10.1111\/dth.15122","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T14:52:09Z","timestamp":1630680729000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real\u2010life data"],"prefix":"10.1155","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-4142","authenticated-orcid":false,"given":"Mustafa","family":"G\u00fcrb\u00fcz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Ankara University Faculty of Medicine  Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-1119","authenticated-orcid":false,"given":"\u0130zzet","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Istanbul University Institute of Oncology  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"Akku\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Ankara University Faculty of Medicine  Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande","family":"Ermi\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology Karadeniz Technical University Faculty of Medicine  Trabzon Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcng\u00f6r","family":"Utkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Ankara University Faculty of Medicine  Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sezai","family":"Vatansever","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Istanbul University Institute of Oncology  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-7116","authenticated-orcid":false,"given":"Faruk","family":"Ta\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Istanbul University Institute of Oncology  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-014-0069-y"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/392151"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14477"},{"key":"e_1_2_10_5_1","volume-title":"Basal Cell Carcinoma","author":"McDaniel B","year":"2020"},{"issue":"5","key":"e_1_2_10_6_1","first-page":"26","article-title":"Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies","volume":"9","author":"Lanoue J","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2503"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16230"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70198-1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.06.003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.37047\/jos.2019-71992"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58117-0"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.012"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.15122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:08:57Z","timestamp":1713960537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.15122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/dth.15122"],"URL":"https:\/\/doi.org\/10.1111\/dth.15122","archive":["Portico"],"relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"value":"1396-0296","type":"print"},{"value":"1529-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"2021-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15122"}}